Brimonidine
4857534
216705889
2008-06-02T21:05:39Z
Crk2002
3704296
{{drugbox
| IUPAC_name = 5-Bromo-''N''-(4,5-dihydro-1''H''-imidazol-2-yl) quinoxalin-6-amine
| width=260
| image = Brimonidine structure.png
| CAS_number = 59803-98-4
| ATC_prefix = S01
| ATC_suffix = EA05
| ATC_supplemental =
| PubChem = 2435
| DrugBank = APRD00034
| C=11 | H=10 | Br=1 | N=5
| molecular_weight = 292.135 g/mol
| bioavailability =
| protein_bound =
| metabolism = liver primarily
| elimination_half-life = 3 hours
| pregnancy_category = B
| legal_status = unknown
| routes_of_administration = Ocular, 1 gtt
}}
'''Brimonidine''' (bri-MOE-ni-deen, brand names Alphagan and Alphagan-P) is a [[medication|drug]] used to treat [[glaucoma|open-angle glaucoma]] or [[ocular hypertension]]. Alphagan is also used to induce [[miosis]] for people suffering from poor night vision after Lasik or PRK surgery.
It acts via decreasing synthesis of [[aqueous humor]], and increasing the amount that drains from the eye. As a treatment for glaucoma, it is usually given in eyedrop form.
Brimonidine is an α<sub>2</sub>-adrenergic receptor agonist.
Alpha 2 agonists, through the activation of the Gi GPCR, inhibit the production of AC. This reduces cAMP and hence Aqueous Humour production by the ciliary body.
==Clinical uses==
Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle
glaucoma or ocular hypertension.
==External links==
* [http://www.alphaganp.com/ Alphagan P product website]
* [http://www.alphaganp.com/ALPHGANP.pdf Alphagan P prescribing information]
==References==
* ''Mosby's Drug Guide for Nurses'' (7th edition; Skidmore) 2007.
{{Antiglaucoma preparations and miotics}}
[[Category:Imidazolines]]
[[Category:Quinoxalines]]